Skip to content

The Impact of Transcranial Magnetic Stimulation on Poor Prognosis in Postherpetic Neuralgia Patients with Mild to Moderate Depression Undergoing Neuromodulation Intervention: A Randomized Double-Blind Placebo-Controlled Trial

The Impact of Transcranial Magnetic Stimulation on Poor Prognosis in Postherpetic Neuralgia Patients with Mild to Moderate Depression Undergoing Neuromodulation Intervention: A Randomized Double-Blind Placebo-Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096978
Enrollment
Unknown
Registered
2025-02-10
Start date
2025-02-12
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic Neuralgia

Interventions

rTMS group:The subjects will receive 10Hz rTMS daily for 2 days before and 3 days the surgery. In the 10Hz rTMS, the stimulation site: M1 area, frequency: 10Hz, intensity: 80% RMT, pulse number: 1500,
Sham stimulation group:The subjects will receive sham rTMS daily for 2 days before and 3 days after surgery. In the sham rTMS, the stimulation site: M1 area, frequency: 0Hz, intensity: 0% RMT, total t

Sponsors

The First Affiliate Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for herpes zoster, with pain persisting for more than 1 month after clinical recovery of the rash; Ages =18 years; VAS pain = 3 points, requiring hospitalization for interventional neuromodulation treatment; with mild to moderate depression (SDS score of 53-72 initial screening, followed by further assessment by a neurologist); no aphasia or cognitive impairment; planned for the first interventional pain management treatment, including pulse radio (PRF) and spinal cord stimulation (SCS); informed consent from the patient and their family.

Exclusion criteria

Exclusion criteria: Severe systemic illness, organic brain damage, intracranial ferromagnetic metal implants (cochlear implants, vagus nerve stimulators etc.); history of psychiatric disorders and psychotropic medication treatment, such as epilepsy; history of implanted processors or implants (pacemakers, artificial heart valves) to vital signs in any part of the body; severe cardiovascular, pulmonary, hepatic, or renal disease; comorbid pain conditions that may interfere with PHN assessment inability to clearly express subjective feelings.

Design outcomes

Primary

MeasureTime frame
Incidence of poor prognosis;

Secondary

MeasureTime frame
The impact of chronic pain on life;Sleep quality;Depression level;patient satisfaction;Degree of fatigue;The feeling of pain;Medication regimen ;pregabalin oral doses ;the need for tramadol ;the need for antidepressants;Incidence of poor prognosis;

Countries

China

Contacts

Public ContactXiaohong Jin

The First Affiliate Hospital of Soochow University

jxhtgzy@163.com+86 183 5240 9837

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 27, 2026